TARO-SUNITINIB CAPSULE

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

SUNITINIB (SUNITINIB MALATE)

Disponibbli minn:

TARO PHARMACEUTICALS INC

Kodiċi ATC:

L01EX01

INN (Isem Internazzjonali):

SUNITINIB

Dożaġġ:

37.5MG

Għamla farmaċewtika:

CAPSULE

Kompożizzjoni:

SUNITINIB (SUNITINIB MALATE) 37.5MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0151642004; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2022-01-07

Karatteristiċi tal-prodott

_Pr_
_TARO-SUNITINIB Product Monograph _
_ Page 1 of 65_
PRODUCT MONOGRAPH
PR
TARO-SUNITINIB
Sunitinib
Capsules
12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib
per capsule (as sunitinib
malate)
Tyrosine Kinase Inhibitor, Anti-Tumour Agent
Taro Pharmaceuticals Inc.
130 East Drive
Brampton, ON
L6T 1C1
Date of Preparation:
January 5, 2022
Submission
Control No.: 235867
_Pr_
_TARO-SUNITINIB Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 65 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION....................................................... 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND
PRECAUTIONS....................................................................................
4
ADVERSE
REACTIONS....................................................................................................15
DRUG INTERACTIONS
....................................................................................................30
DOSAGE AND ADMINISTRATION
.................................................................................31
OVERDOSAGE
..................................................................................................................32
ACTION AND CLINICAL
PHARMACOLOGY...............................................................32
STORAGE AND STABILITY
............................................................................................36
SPECIAL HANDLING
INSTRUCTIONS..........................................................................36
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................36
PART II: SCIENTIFIC INFORMATION
.............................................................................37
PHARMACEUTICAL INFORMATION
.............